Unity Biotechnology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Unity Biotechnology generated cash of -$37,088,000, which is more than the previous year. Cash used in financing activities reached the amount of -$16,340,000 last year. Net change in cash is therefore $7,067,000.
Cash Flow
| 2016 | -16.39M | -2.74M | 107.93M |
|---|---|---|---|
| 2017 | -38.35M | -86.30M | 42.77M |
| 2018 | -56.62M | -72.20M | 136.93M |
| 2019 | -72.42M | 67.95M | 27.43M |
| 2020 | -78.33M | -5.20M | 63.87M |
| 2021 | -45.06M | 39.31M | 20.84M |
| 2022 | -51.02M | -24.54M | 54.85M |
| 2023 | -37.08M | 60.49M | -16.34M |
UBX Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 12.73M | 34.35M | 19.25M | 38.91M | 15.94M | 7.84M | 89.73M | 940K |
Operating activities | ||||||||
Net income | -39.86M | -59.92M | -60.72M | -93.84M | -82.17M | -76.39M | -44.65M | -30.40M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.18M | 2.18M | 2.88M | 3.44M | 2.66M | 2.18M | 1.30M | 153K |
Stock-based compensation expense | 7.41M | 9.37M | 11.55M | 13.81M | 10.85M | 0 | 3.03M | 224K |
| Deferred income tax benefit | 7.41M | 9.37M | 11.55M | 13.81M | 10.85M | 0 | 3.03M | 224K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 1.38M | -1.38M | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -410K | -194K | -573K | -2.64M | -227K | 2.22M | 1.19M | 198K |
Cash generated by operating activities | -37.08M | -51.02M | -45.06M | -78.33M | -72.42M | -56.62M | -38.35M | -16.39M |
Investing activities | ||||||||
Purchases Of Investments | -28.60M | -98.82M | -81.49M | -138.48M | -119.27M | -204.58M | -134.46M | -500K |
Investments In Property Plant And Equipment | -11K | -96K | -195K | -646K | -1.58M | -1.26M | -1.68M | -2.24M |
Acquisitions Net | 0 | 378K | -39.50M | 4.56M | -69.53M | 0 | 0 | 0 |
Cash generated by investing activities | 60.49M | -24.54M | 39.31M | -5.20M | 67.95M | -72.20M | -86.30M | -2.74M |
Financing activities | ||||||||
Common Stock Issued | 5.10M | 58.06M | 18.57M | 37.27M | 26.08M | 0 | 42.83M | 107.93M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -37K | 0 |
Repayments of term debt | -20M | 0 | -68K | -405K | -73K | -74K | -55K | -16.88M |
Cash used in financing activities | -16.34M | 54.85M | 20.84M | 63.87M | 27.43M | 136.93M | 42.77M | 107.93M |
Net Change In Cash | 7.06M | -20.71M | 15.09M | -19.66M | 22.97M | 8.10M | -81.88M | 88.79M |
Cash at end of period | 19.80M | 13.63M | 34.35M | 19.25M | 38.91M | 15.94M | 7.84M | 89.73M |
| Data source | Data source | Data source | Data source | Data source | Data source |